Development of dyskinesias induced by treatment for parkinson's disease: Potential role of first exposure to L-DOPA (priming);Developpement des dyskinesies provoquees par le traitement de la maladie de Parkinson: Role de la premiere exposition a la L-DOPA (ou phenomene du << priming >>)

Revue Neurologique

Volumn 156, Issue 3, 2000, Pages 224-235

  Damier, P ^a   Tremblay, L ^b   Feger J ^b   Hirsch, E C ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; DOPAMINE 2 RECEPTOR; ENKEPHALIN; SUBSTANCE P;

DISEASE COURSE; DYSKINESIA; HUMAN; INTERNALIZATION; NEUROTOXICITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; ACTIVE TRANSPORT; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; EFFERENT NERVE; HAPLORHINI; METABOLISM; NERVE CELL PLASTICITY; NERVE TRACT; PHYSIOLOGY; TIME;

ANIMALS; ANTIPARKINSON AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; HAPLORHINI; HUMANS; LEVODOPA; NEURAL PATHWAYS; NEURONAL PLASTICITY; NEURONS, EFFERENT; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; SUBSTANCE P; TIME FACTORS;

EID: 0034153474     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. ALBIN RL, YOUNG AB, PENNEY JB. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci, 12: 366-375.
2. ALBIN RL, YOUNG AB, PENNEY JB. (1995). The functional anatomy of disorders of the basal ganglia. Trends Neurosci, 18: 63-64.
3. ANGLADE P, TSUJI S, HIRSCH EC, JAVOY-AGID F, AGID Y. (1993). Ultrastructural relations between nigrostriatal dopaminergic neurons and cholinergic nerve endings in the human brain. Histol Histopathol, 8: 501-504.
4. ANGLADE P, TSUJI S, JAVOY-AGID F, AGID Y, HIRSCH EC. (1995). Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. Ann Neurol, 37: 265-272.
5. ANGLADE P, BLANCHARD V, RAISMAN-VOZARI R, et al. (1996). Is dopaminergic cell death accompanied by concomitant nerve plasticity? Adv Neurol, 69: 195-208.
6. BALLARD PA, TETRUD JW, LANGSTON JW. (1985). Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology, 35: 949-956.
7. 3H]spiperone binding. Brain Res, 379: 294-299.
8. BEJJANI B-P, ARNULF I, DEMERET S, BONNET A-M, DAMIER P, AGID YA. (1998). Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible? Mov Disord, 13 (Suppl. 2): 118 (Abstract).
9. BLANCHET P, BEDARD PJ, BRITTON DR, KEBABIAN JW. (1993). Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther, 267: 275-279.
10. BLANCHET PJ, CALON F, MARTEL J-C, et al. (1995). Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther, 272: 854-859.
11. BLANCHET PJ, KONITSIOTIS S, CHASE TN. (1998). Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys. Mov Disord, 13: 798-802.
12. BLOCK G, LISS C, REINES S, IRR J, NIBBELINK DC. (1997). The FIRST study group comparison of immediate release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol, 37: 23-27.
13. BOKOBZA B, RUBERG M, SCATTON B, JAVOY-AGID F, AGID Y. (1984). [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol, 99: 167-175.
14. BORDET R, RIDRAY S, CARBONI S, DIAZ J, SOKOLOFF P, SCHWARTZ JC. (1997). Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA, 94: 3363-3367.
15. BOYCE S, RUPNIAK NM, STEVENTON MJ, IVERSEN SD. (1990a). Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol, 13: 448-458.
16. BOYCE S, RUPINAK NMJ, TYE S, STEVENTON M, IVERSEN SD. (1990b). Modulatory rôle for CCK-B anatagonists in Parkinson's disease. Clin Neuropharmacol, 13: 339-347.
17. BRAVI D, MOURADIAN MM, ROBERTS JW, DAVIS TL, SOHN YH, CHASE TN. (1994). Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol, 36: 27-31.
18. BROTCHIE JM. (1998). Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord, 13: 871-876.
19. BROUSSOLLE E. (1999). Arguments en faveur du traitement initial de la maladie de Parkinson par la L-dopa. Rev Neurol, 155: 27-33.
20. CROSSMAN AR, MITCHELL IJ, SAMBROOK MA, JACKSON A. (1988). Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex: the site of drug action and a hypothesis for the neural mechanisms of chorea. Brain, 111: 1211-1233.
21. DEFER G. (1999). Controverse sur le traitement initial de la maladie de Parkinson : L-dopa ou agonistes dopaminergiques ? Rev Neurol, 155: 43-45.
22. DELONG MR. (1990). Primate model of movement disorders of basal ganglia origin. Trends Neurosci, 13: 281-289.
23. DUMARTIN B, CAILLE I, GONON F, BLOCH B. (1998). Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci, 18: 1650-1661.
24. DUPONT E, ANDERSEN A, BOAS J, et al. (1996). Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of do novo parkinsonian patients. Acta Neurol Scand, 93: 14-20.
25. FILION M, TREMBLAY L, BEDARD PJ. (1991). Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res, 547: 152-161.
26. GOETZ CG, TANNER CM, NAUSEDIA PA. (1981). Weekly drug holiday in Parkinson disease. Neurology, 31: 1460-1462.
27. GOLBE LI. (1991). Young-onset Parkinson's disease: a clinical review. Neurology, 41: 168-173.
28. GOMEZ-MANCILLA B, BEDARD PJ. (1991). Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther, 259: 409-413.
29. GOULET M, GRONDIN R, BLANCHET PJ, BEDARD PJ, DI PAOLO T. (1996). Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administrated in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res, 719: 129-137.
30. GRONDIN R, BEDARD PJ, BRITTON DR, SHIOSAKI K. (1997). Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology, 49: 421-426.
31. GUTTMAN M, SEEMAN P, REYNOLDS GP, RIEDERER P, JELLINGER K, TOURTELLOTTE WW. (1986). Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol, 19: 487-492.
32. HARDIE RJ, MALCOLM SL, LEES AJ, STERN GM, ALLEN JG. (1986). The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol, 22: 429-436.
33. HASSANI O-K, FRANCOIS C, YELNIK J, FEGER J. (1997). Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res, 749: 88-94.
34. HERRERO MT, AUGOOD SJ, HIRSCH EC, JAVOY-AGID F, LUQUIN MR, AGID Y, et al. (1995). Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience, 68: 1189-1198.
35. HOKFELT T. (1991). Neuropeptides in perspective: the last ten years. Neuron, 7: 867-879.
36. HURLEY MJ, JOLKKONEN J, STUBBS CM, JENNER P, MARSDEN CD. (1996a). Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res, 709: 259-264.
37. HURLEY MJ, STUBBS CM, JENNER P, MARSDEN CD. (1996b). D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Letters, 214: 75-78.
38. JENNER P. (1997). Mechanisms of motor complications in Parkinson's disease - a discussion. In : Olanow W., Obeso J. (eds), Beyond the decade of the brain - vol 2: dopamine agonists in early Parkinson's disease, Wells Medical Limited, Royal Tunbridge Wells, pp. 115-128.
39. LANGSTON JW, BALLARD P, TETRUD JW, IRWIN I. (1983). Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219: 979-980.
40. LAVOIE B, SMITH Y, PARENT A. (1989). Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J Comp Neurol, 289: 36-52.
41. LEES AJ, STERN GM. (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 44: 1020-1023.
42. LEVY R, HAZRATI L-N, HERRERO M-T, VILA M, HASSANI O-K, MOUROUX M, et al. (1997). Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience, 76: 335-343.
43. MARCONI R, LEFEVRE-CAPARROS D, BONNET AM, VIDAILHET M, DUBOIS B, AGID Y. (1994). Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord, 9: 2-12.
44. MARSDEN CD, PARKES JD. (1977). Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet, 1: 345-349.
45. MATSUMARA M, TREMBLAY L, RICHARD H, FILLION M. (1995). Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum. Neuroscience, 65: 59-70.
46. MELAMED E, HEFTI F, WURTMAN RJ. (1982). Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Isr J Med Sci, 18: 159-163.
47. MISSALE C, NASH SR, ROBINSON SW, JABER M, CARON MG. (1998). Dopamine receptors: from structure to function. Physiol Rev, 78: 189-225.
48. MONTASTRUC JL, RASCOL O, SENARD JM, RASCOL A. (1994). A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry, 57: 1034-1038.
49. MURER MG, DZIEWCZAPOLSKI G, MENALLED LB, et al. (1998). Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol, 43: 561-575.
50. MURIEL MP, BERNARD V, CAILLÉ I, ABROUS OLN, AGID Y, BLOCH B, HIRSCH EC. (1999). L-dopa induces a cytoplasmic localization of D1 receptors in Parkinson's disease. Ann Neurol (sous presse).
51. NAGATSU T, KANAMORI T, KATO T, IIZUKA R, NARABAYASHI H. (1978). Dopamine-stimulated adenylate cyclase activity in the human brain: changes in Parkinsonism. Biochem Med, 19: 360-365.
52. NISBET AP, FOSTER OJ, KINGSBURY A, et al. (1995). Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 66: 361-376.
53. OBESO JA, LUQUIN MR, VAAMONDE J, GRANDAS F, MARTINEZ LAGE JM. (1987). Continuous dopaminergic stimulation in Parkinson's disease. Can J Neurol Sci, 14 (Suppl 3): 488-492.
54. OBESO JA, RODRIGUEZ MC, DELONG MR. (1997). Basal ganglia pathophysiology. A critical review. Adv Neurol, 74: 3-18.
55. PEARCE RK, BANERJI T, JENNER P, MARSDEN CD. (1998). De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord, 13: 234-241.
56. PAPA SM, ENGBER TM, KASK AM, CHASE TN. (1994). Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res, 662: 69-74.
57. PIEROT L, DESNOS C, BLIN J, et al. (1988). D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci, 86: 291-306.
58. POEWE W, KLEEDORFER B, WAGNER M, BOSCH S, SCHELOSKY L. (1993). Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol, 60: 656-659.
59. QUINN N, PARKER D, JANOTA I, MARSDEN CD. (1986). Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2kg) plus decarboxylase inhibitor over a four-year period. Mov Disord, 1: 65-68.
60. RASCOL A, GUIRAUD B, MONTASTRUC JL, DAVID J, CLANET M. (1979). Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry, 42: 143-150.
61. RASCOL O. (1999). Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques. Rev Neurol, 155: 35-42.
62. RAISMAN R, CASH R, RUBERG M, JAVOY-AGID F, AGID Y. (1985). Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol, 113: 467-468.
63. RIEDERER P, RAUSCH WD, BIRKMAYER W. JELLINGER K, DANIELCZYK W. (1978). Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. J Neural Transm Suppl, (14): 153-161.
64. RINNE JO, RINNE JK, LAAKSO K, LONNBERG P, RINNE UK. (1985). Dopamine D-1 receptors in the parkinsonian brain. Brain Res, 359: 306-310.
65. ROBERTSON RG, FARMERY SM, SAMBROOK MA, CROSSMAN AR. (1989). Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res, 476: 317-322.
66. ROBINSON TE, WHISHAW IQ. (1988). Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res, 450: 209-224.
67. SAMBROOK MA, CROSSMAN AR, MITCHELL I, ROBERTSON RG, CLARKE CE, BOYCE S. (1989). The basal ganglia mechanisms mediating primate models of movement disorders. In : Crossman AR, MA Sambrook (eds.), Neural Mechanisms in Disorders of Movement. Current Problems in Neurology: 9, Libbey, London, pp. 123-144.
68. TEL BC, ZENG B-Y, PEARCE RKB, ROSE S, JENNER P, MARSDEN CD. (1998). Changes in striatal preproenkephalin A (PPE-A) and preprotachykinin (PPT) mRNA expression: the effects of L-dopa, Bromocriptin, and Ropinirole in MPTP-treated marmosets. Neurology, 50: A135(Abstract).
69. TREMBLAY L, FILION M. (1989). Responses of pallidal neurons to striatal stimulation in intact waking monkeys. Brain Res. 498: 1-16.
70. TURJANSKI N, LEES AJ, BROOKS DJ. (1997). In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology, 49: 717-723.
71. WEINER WJ, KOLLER WC, PERLIK S, NAUSIEDA PA, KLAWANS HL. (1980). Drug holiday and management of Parkinson disease. Neurology, 30: 1257-1261.
72. ZHANG WQ, TILSON HA, NANRY KP, HUDSON PM, HONG JS, STACHOWIAK MK. (1988). Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res, 461: 335-342.